Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

(MedPage Today) — The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced.
The rapid-acting L-type calcium channel blocker is indicated…

Source link : https://www.medpagetoday.com/cardiology/arrhythmias/119016

Author :

Publish date : 2025-12-15 19:08:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

Novel Pills Promising in Relapsed/Refractory Multiple Myeloma

FDA Approves Uplizna for Generalized Myasthenia Gravis

Related Posts

Next DSM Insights; FDA Reviewing Non-Stimulant ADHD Drug; 10M People Microdosing

Viral and Nonviral NICU Infection Rates Diverged During the COVID Pandemic

NIH Data Misused for ‘Race Science’; RFK Jr.’s Autism Committee; NIH Panels at Risk

Study Suggests Some Tap Water May Raise Blood Pressure

Juvenile Localized Scleroderma: MMF Matches Methotrexate

AI model from Google’s DeepMind reads recipe for life in DNA

Next DSM Insights; FDA Reviewing Non-Stimulant ADHD Drug; 10M People Microdosing

Viral and Nonviral NICU Infection Rates Diverged During the COVID Pandemic

NIH Data Misused for ‘Race Science’; RFK Jr.’s Autism Committee; NIH Panels at Risk

Study Suggests Some Tap Water May Raise Blood Pressure

Juvenile Localized Scleroderma: MMF Matches Methotrexate

AI model from Google’s DeepMind reads recipe for life in DNA

The Epstein-Berr virus infects most of us – but why do only some get very ill?

UK Rejects Class A Status for Ketamine After Review

Categories

Archives